Martine van Vugt
Director/Board Member chez SCANDION ONCOLOGY A/S
Profil
Martine J.
van Vugt is currently an Independent Director at Scandion Oncology A, a Director at Hollandbio, the Chief Strategy Officer & Executive Vice President at Genmab A, an Independent Member-Supervisory Board at TME Pharma NV, and a Member-Supervisory Board at Immagene BV.
Dr. van Vugt holds a doctorate degree from the University of Utrecht and a graduate degree from Wageningen University.
Postes actifs de Martine van Vugt
| Sociétés | Poste | Début |
|---|---|---|
| GENMAB A/S | Corporate Officer/Principal | 29/03/2023 |
| TME PHARMA N.V. | Director/Board Member | 24/06/2021 |
| SCANDION ONCOLOGY A/S | Director/Board Member | 01/04/2022 |
Immagene BV
 Immagene BV Pharmaceuticals: MajorHealth Technology Immagene BV is a private biotech company based in the Netherlands that is dedicated to developing next-generation precision immuno-oncology treatments. Immagene is committed to transforming cancer treatment and has a focus on precision medicine. The Dutch company was founded on world-leading research from the Netherlands Cancer Institute and drug R & D expertise from industry veterans. The company was founded by Maarten Ligtenberg, Christian Blank, and Daniel Peeper, with Maarten Ligtenberg serving as the CEO since incorporation. | Director/Board Member | - |
| Hollandbio | Director/Board Member | - |
Formation de Martine van Vugt
| University of Utrecht | Doctorate Degree |
| Wageningen University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GENMAB A/S | Health Technology |
| TME PHARMA N.V. | Health Technology |
| SCANDION ONCOLOGY A/S | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Hollandbio | |
Immagene BV
Immagene BV Pharmaceuticals: MajorHealth Technology Immagene BV is a private biotech company based in the Netherlands that is dedicated to developing next-generation precision immuno-oncology treatments. Immagene is committed to transforming cancer treatment and has a focus on precision medicine. The Dutch company was founded on world-leading research from the Netherlands Cancer Institute and drug R & D expertise from industry veterans. The company was founded by Maarten Ligtenberg, Christian Blank, and Daniel Peeper, with Maarten Ligtenberg serving as the CEO since incorporation. | Health Technology |
